BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $85 from $81 and keeps a Buy rating on the shares. The company’s SLK is well-positioned to deliver best in class/disease efficacy in upcoming 16-week Phase 3 VELA data expected around September 2025, the analyst tells investors in a research note. Enrollment has completed in both VELA trials in 12 months, representing the fastest enrollment timeline for any Phase 3 program in hidradenitis suppurativa by a wide margin, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy Rating
- MoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy Rating
- MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating
- MoonLake Immunotherapeutics Hosts Capital Markets Day
- MoonLake Immunotherapeutics Secures $500M Financing for Growth